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Abstract
Allogeneic haematopoietic stem cell transplantation (HSCT) is a frequent curative therapy for numerous
haematological malignancies. However, HSCT is limited by the occurrence of graft-versus-host disease
(GVHD), with current therapies restricted to general immunosuppression. Activation of the P2X7 receptor
by extracellular adenosine triphosphate (ATP) causes inflammation and tissue damage in GVHD. Short-term
pharmacological blockade of P2X7 has been shown to reduce clinical disease and/or reduce inflammatory
markers in allogeneic and humanized mouse models of GVHD. The current study demonstrates that long-
term P2X7 blockade by intra-peritoneal injection of Brilliant Blue G (BBG) thrice weekly for up to 10 weeks
did not impact human (h) peripheral blood mononuclear cell (PBMC) engraftment, predominantly T cells, in
blood at 3 weeks post-hPBMC injection or in spleens at end-point in humanized mice. Histological analysis
demonstrated long-term BBG treatment reduced leukocyte infiltration in the livers of humanized mice.
Immunohistochemical analysis demonstrated that BBG treatment reduced liver apoptosis. Long-term BBG
treatment did not alter clinical disease, mRNA expression of pro-inflammatory markers in tissues or serum
human interferon (IFN)-γ concentrations. Therefore, this study demonstrates that P2X7 activation plays a
role in GVHD pathogenesis in the livers of humanized mice, supporting a role for this receptor in GVHD
development in HSCT recipients.
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Allogeneic haematopoietic stem cell transplantation (HSCT) is a frequent curative therapy for 
numerous haematological malignancies. However, HSCT is limited by the occurrence of 
graft-versus-host disease (GVHD), with current therapies restricted to general 
immunosuppression. Activation of the P2X7 receptor by extracellular adenosine triphosphate 
(ATP) causes inflammation and tissue damage in GVHD. Short-term pharmacological 
blockade of P2X7 has been shown to reduce clinical disease and/or reduce inflammatory 
markers in allogeneic and humanized mouse models of GVHD. The current study 
demonstrates that long-term P2X7 blockade by intra-peritoneal injection of Brilliant Blue G 
(BBG) thrice weekly for up to 10 weeks did not impact human (h) peripheral blood 
mononuclear cell (PBMC) engraftment, predominantly T cells, in blood at 3 weeks post-
hPBMC injection or in spleens at end-point in humanized mice. Histological analysis 
demonstrated long-term BBG treatment reduced leukocyte infiltration in the livers of 
humanized mice. Immunohistochemical analysis demonstrated that BBG treatment reduced 
liver apoptosis. Long-term BBG treatment did not alter clinical disease, mRNA expression of 
pro-inflammatory markers in tissues or serum human interferon (IFN)-γ concentrations. 
Therefore, this study demonstrates that P2X7 activation plays a role in GVHD pathogenesis 
in the livers of humanized mice, supporting a role for this receptor in GVHD development in 




Cellular Immunology  Geraghty, Watson & Sluyter 2019 




Allogeneic haematopoietic stem cell transplantation (HSCT) is a frequent curative method for 
various haematological malignancies. However, a major side effect of this treatment is graft-
versus-host disease (GVHD). GVHD occurs in approximately half of HSCT recipients [1] 
and results in damage to the liver, gastrointestinal tract and skin, with the liver affected in 
approximately 50% of GVHD patients [2]. GVHD emerges due to transplanted effector T 
cells mounting an immune response against the host [3]. This immune response is driven by 
release of cytokines and danger associated molecular patterns (DAMP), which causes antigen 
presenting cells to release cytokines resulting in activation of T cells [4-6]. T cell activation 
leads to proliferation and differentiation of T cell subsets such as Th1 cells which release 
interferon (IFN)-γ [4, 5], and Th17 cells which release interleukin (IL)-17, resulting in 
inflammatory damage [7, 8]. Current therapies are largely limited to general 
immunosuppression through the use of steroids [9], highlighting the need for better therapies. 
Targeting a pathway in one of the above stages of GVHD represents a potential therapeutic 
strategy. Purinergic signalling is an important pathway of immune cell signalling [10] and 
plays important roles in transplantation [11-13]. Of all the purinergic receptors, the P2X7 
receptor is the most widely studied in immune and inflammatory responses [14]. Activation 
of P2X7 induces a number of downstream effects including DC activation and cytokine 
release [15], T cell activation [16] and inhibition of regulatory T cells [17]. Thus, given the 
central role of these immune processes in GVHD, blockade of P2X7 represents a potential 
therapeutic approach to limit GVHD development. In allogeneic mouse models the DAMP, 
adenosine triphosphate (ATP), is released from damaged and dying cells, to promote GVHD 
[18]. ATP exacerbates GVHD by activating P2X7 in allogeneic mouse models [18-20]. Short 
term pharmacological blockade of P2X7 with either KN-62, pyridoxalphosphate-6-
azophenyl-2',4'-disulfonic acid or stavudine during the first week post-transplantation can 
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extend survival of recipient mice in these models [18, 19]. Whilst, P2X7 blockade with 
Brilliant Blue G (BBG) (50 or 75 mg/kg) twice per week for 4 weeks reduces weight loss and 
liver GVHD in an allogeneic mouse model [20]. Finally, our group recently demonstrated 
that short-term blockade of P2X7 with BBG (50 mg/kg, days 0, 2, 4, 6, 8) reduced serum 
human (h) IFN-γ and tissue inflammation in a humanized non-obese diabetic severe 
combined immunodeficient IL-2 gamma receptor null (NOD-SCID-IL2Rγnull; NSG) mouse 
model of GVHD [21].    
To further extend the above observations [18-21] to humans, the current study investigated 
the effect of long-term P2X7 blockade with BBG (50 mg/kg; thrice weekly for up to 10 
weeks) in a humanized NSG mouse model of GVHD. Similar to our previous study [21], 
injection of BBG did not impact human leukocyte engraftment, weight loss, clinical score or 
survival. Notably, this regime reduced leukocyte infiltration and apoptosis in the livers of 
mice, supporting a role for P2X7 activation in GVHD pathogenesis in the liver. 
 
2. Materials and Methods 
2.1. Humanized mouse model of GVHD 
Experiments with human blood and mice were approved by the Human and Animal Ethics 
Committees, respectively (University of Wollongong, Wollongong, Australia). Humanized 
NSG mice were established as described [21]. Briefly, hPBMCs, isolated by density 
centrifugation using Ficoll-Paque PLUS (GE Healthcare; Uppsala, Sweden), were injected 
intra-peritoneally (i.p) (10 x 106 hPBMCs/mouse) into female NSG mice aged 5-7 weeks 
(Westmead Animal Research Facility, Westmead, Australia) housed at the University of 
Wollongong. Mice were injected i.p. 2 hours later with 200 μL of saline (saline group) or 
saline containing BBG (Sigma-Aldrich; St Louis, MO, USA) (50 mg/kg; BBG group), then 
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thrice weekly (every second or third day apart) for up to 10 weeks. At 3 weeks post-hPBMC 
injection, engraftment was examined by immunophenotyping of tail vein blood. Mice were 
monitored up to 10 weeks for signs of clinical GVHD using a scoring system, giving a total 
clinical score out of 10 as described [21] and euthanized at 10 weeks post-hPBMC injection, 
or earlier if the clinical score was ≥ 8 or weight loss was ≥ 10%, as per the approved ethics 
protocol.  
2.2. Immunophenotyping by flow cytometry 
Tail vein blood and spleen cells were obtained from mice and lyzed with ammonium chloride 
potassium buffer and immunophenotyped as described [21] with the addition of an 
allophycocyanin conjugated mouse anti-hCD56 monoclonal antibody (clone: B159) (BD, San 
Jose, CA, USA). Data was collected using a BD Fortessa-X20 Flow Cytometer using band 
pass filters of 525/50 for fluorescein isothiocyanate, 586/15 for R-phycoerythrin, 695/40 for 
peridinin chlorophyll protein and 670/30 for allophycocyanin. The relative percentages of 
cells were analyzed using FlowJo software v8.7.1 (TreeStar Inc.; Ashland, OR, USA) (Fig. 
S1 and Fig. S2).  
2.3. Histological, immunohistochemical and image analysis  
Some formalin-fixed tissue sections (5 μm) were stained with haematoxylin and eosin 
(POCD; Artarmon, Australia) for histological analysis. Other formalin-fixed tissue sections 
were stained with either rabbit anti-hCD3 mAb (clone: EP449E) (Abcam, Cambridge, UK) 
and haematoxylin as described [21] or an In situ Apoptosis Detection Kit (Abcam) as per the 
manufacturer’s instructions. Total numbers of leukocyte and hCD3+ T cell infiltrates and 
apoptotic cells in livers were quantified from captured images (Leica DMRB microscope, 
Wetzlar, Germany) using FIJI is just ImageJ (FIJI) software [22]. Data is represented as the 
total number of cells measured per field of view. Epidermal thickness of skin sections was 
measured as described [23]. 
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2.4. Quantitative real-time PCR  
RNA was isolated using TRIzol reagent (Thermo Fisher Scientific) and converted to cDNA 
using the qScript cDNA Synthesis Kit (Quanta Biosciences, Beverly, MA, USA) as per the 
respective manufacturer’s instructions. Quantitative real-time PCR (qPCR) was performed as 
described [21] with the addition of a human tumor necrosis factor (TNF)-α (Hs01113624_g1) 
primers (Thermo Fisher Scientific). Human gene expression was normalized to cDNA from 
hPBMCs, directly isolated from a human donor. Murine gene expression was normalized to 
cDNA from a spleen of a BALB/c mouse [24]. 
2.5. ELISAs 
Serum was obtained from mice as described [21], and hIFN-γ and hIL-17 concentrations 
determined using respective Ready-Set-Go! ELISA Kits (eBioscience, San Diego, CA, USA) 
as per the manufacturer’s instructions.  
2.6. Statistical Analysis 
Data is given as mean ± standard deviation (SD). Statistical differences were determined 
using Student’s t-test for single comparisons or one-way analysis of variance (ANOVA) with 
Tukey’s post-hoc test for multiple comparisons. Weight and clinical score over time were 
compared using a repeated measures two-way ANOVA with Tukey’s post-hoc test for 
multiple comparisons. Survival (median survival time; MST) was compared using the log-
rank (Mantel-Cox) test. Mortality was compared using Fisher’s exact test. All statistical 
analyses and graphs were generated using GraphPad Prism 5 for PC (GraphPad Software, La 
Jolla, CA, USA). P < 0.05 was considered significant for all tests. 
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3.1. BBG does not impact engraftment of human cells in NSG mice 
To determine if long-term P2X7 blockade can ameliorate disease development in a 
humanized mouse model of GVHD, NSG mice injected with hPBMCs were subsequently 
injected with the P2X7 antagonist BBG [25] at 50 mg/kg or with saline thrice weekly for up 
to 10 weeks. To first investigate if human cell engraftment was affected by BBG treatment, 
flow cytometric analysis of blood was conducted at 3 weeks post-hPBMC injection 
(Supplementary Fig. 1). Mice injected with BBG demonstrated a similar frequency of human 
leukocytes (13.2 ± 7.6% hCD45+ mCD45- cells, n = 10) compared to mice injected with 
saline (control) (9.7 ± 7.3% hCD45+ mCD45- cells, n = 7) (P = 0.3561) (Fig. 1a). T cells 
comprized the majority of hCD45+ cells, and the frequencies of T cells did not vary between 
mice injected with BBG (93.2 ± 4.4% hCD3+ hCD56- cells, n = 10) or saline (91.6 ± 5.5% 
hCD3+ hCD56- cells, n = 7) (P = 0.5188) (Fig. 1b). In all mice, there was a small population 
of hCD3+ hCD56+ cells, potentially natural killer T (NKT) cells [26], but the frequency of 
these cells did not vary between mice injected with BBG (3.1 ± 3.5% hCD3+ hCD56+ cells, n 
= 10) or saline (3.3 ± 2.7% hCD3+ hCD56+ cells, n = 7) (P = 0.8768) (Fig. 1c). Both groups 
of mice also demonstrated engraftment of a small proportion of natural killer (NK) cells 
(hCD3- hCD56+), which did not significantly differ between mice injected with BBG (1.0 ± 
1.0% hCD3- hCD56+ cells, n = 10) or saline (2.3 ± 2.0% hCD3- hCD56+ cells, n = 7) (P = 
0.1067) (Fig. 1d). Finally, there was a small population of cells that were neither T, NKT nor 
NK cells; the frequency of which did not vary between mice injected with BBG (2.7 ± 2.5% 
hCD3- hCD56- cells, n = 10) or saline (2.8 ± 2.8% hCD3- hCD56- cells, n = 7) (P = 0.9854) 
(Fig. 1e).  
Splenocyte analysis at end-point (Supplementary Fig. 2) showed human leukocytes 
comprized the majority of total murine and human leukocytes. Mice injected with BBG 
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exhibited a similar frequency of human leukocytes (76.7 ± 9.7% hCD45+ mCD45- cells, n = 
10) compared to mice injected with saline (71.4 ± 16.2% hCD45+ mCD45- cells, n = 7) (P = 
0.4308) (Fig. 1f). Similar to engraftment at 3 weeks post-hPBMC injection, T cells 
comprized the majority of human leukocytes in the spleen, with mice injected with BBG 
(86.4 ± 15.7% hCD3+ hCD56- cells, n = 10) or saline (96.1 ± 4.9% hCD3+ hCD56- cells, n = 
7) demonstrating similar frequencies of T cells (P = 0.1390) (Fig. 1g). Again, there was a 
small population of hCD3+ hCD56+ cells, and the percentage of these cells did not vary 
between mice injected with BBG (1.3 ± 1.7% hCD3+ hCD56+ cells, n = 10) or saline (0.9 ± 
0.3% hCD3+ hCD56+ cells, n = 7) (P = 0.5154) (Fig. 1h). Few mice demonstrated 
engraftment of NK cells in spleens at time of euthanasia, which did not significantly differ 
between mice injected with BBG (0.7 ± 1.5% hCD3- hCD56+ cells, n = 10) or saline (0.1 ± 
0.1% hCD3- hCD56+ cells, n = 7) (P = 0.3064) (Fig. 1i). Finally, there was a remaining 
population of cells that were neither T, NKT nor NK cells; the frequency of which did not 
vary between mice injected with BBG (10 ± 12.6% hCD3- hCD56- cells, n = 10) or saline 
(3.0 ± 5.1% hCD3- hCD56- cells, n = 7) (P = 0.1868) (Fig. 1j). 
Human T cell analysis (hCD3+) in spleens at end-point (Supplementary Fig. 2) revealed that 
mice injected with BBG or saline contained similar frequencies of hCD4+ T cells (71.3 ± 
13.4%, n = 10 vs. 75.6 ± 8.4%, n = 7, respectively, P = 0.5345) and hCD8+ T cells (17.9 ± 
8.3%, n = 10 vs 14.6 ± 5.2%, n = 7, respectively, P = 0.4500) (Fig. 1k). In mice injected with 
BBG or saline, the percentages of hCD4+ T cells were significantly greater than that of 
hCD8+ T cells (both P < 0.0001 and P < 0.0001, respectively) (Fig. 1k).  
3.2. BBG does not prevent clinical GVHD in NSG mice 
For up to 10 weeks, mice were monitored for weight loss and signs of GVHD. All mice 
injected with BBG or saline exhibited weight loss from 4 weeks, with similar weight loss 
between groups over the course of the study (P = 0.2853) (Fig. 2a). Both groups of mice 
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began to show signs of mild GVHD from day 35, and mice injected with BBG or saline had 
similar clinical scores at end-point (5.8 ± 1.7, n = 10 vs. 5.9 ± 2.0, n = 7, respectively; P = 
0.9494), and mean clinical scores over 10 weeks (P = 0.1286) (Fig. 2b). Similar survival was 
also observed between mice injected with BBG (mortality of 90%, n = 10) or saline 
(mortality of 86.7%, n = 7) (P = 1.000) (Fig. 2c). Mice injected with BBG or saline also 
demonstrated similar MSTs (45.5 days vs. 52.0 days, respectively) (P = 0.3014) (Fig. 2c). 
3.3. BBG reduces leukocyte infiltration and apoptosis in livers of NSG mice 
Short-term BBG has been shown to partly reduce leukocyte infiltrates, predominantly T cells, 
and apoptosis in GVHD target organs including liver, small intestine and skin in humanized 
NSG mice [21]. Therefore, to assess if long-term BBG treatment could reduce leukocyte 
infiltration and damage, target tissues from humanized NSG mice were analyzed via 
histology. There were no histological differences in the small intestines or skin, including 
epidermal thickening, of BBG- and saline-injected mice (Supplementary Fig. 3). However, 
livers from mice injected with BBG demonstrated reduced histological damage with less 
apoptotic cells (Fig 3a). Image analysis demonstrated a significant 52% reduction in 
leukocytes in livers from BBG-injected mice (517 ± 244 cells/field of view; n = 9) compared 
to saline-injected mice (1082 ± 324 cells/field of view; n = 6) (P = 0.0020) (Fig. 3a). 
To determine the identity of the cells above (Fig. 3a), immunohistochemistry using an anti-
hCD3 mAb was conducted. Image analysis demonstrated a 55% reduction in CD3+ cell 
infiltration in livers from BBG-injected mice (117 ± 157 cells/field of view; n = 4) compared 
to saline-injected mice (263 ± 404 cells/field of view; n = 4), however this difference did not 
reach statistical significance (P = 0.5263) (Fig. 3b). Moreover, the number of hCD3+ T cells 
detected (Fig. 3b) represented only 24% of the total leukocytes detected by histology (Fig. 
3a). Finally, an In Situ Apoptosis detection kit was used to confirm that there was reduced 
apoptosis in the liver. Image analysis demonstrated there was a significant 57% decrease in 
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apoptotic cells in livers from BBG-injected mice (65 ± 32 cells/field of view; n = 4) 
compared to saline-injected mice (150 ± 47 cells/field of view; n = 4) (P = 0.0244) (Fig. 3d). 
 
3.4. BBG does not impact cytokine expression in the liver of NSG mice 
IFN-γ, IL-17 and TNF-α are important pro-inflammatory cytokines implicated in GVHD 
pathogenesis [7, 8]. To investigate if long-term BBG treatment alters these cytokines in the 
liver, hIFN-γ, hIL-17 and hTNF-α expression were analyzed by qPCR. hIFN-γ expression 
was similar in mice injected with BBG (2.8 ± 0.8, n = 7) or saline (3.0 ± 1.6, n = 7) (P = 
0.7347) (Fig. 4a). There was a two-fold increase hIL-17 in mice injected with BBG (4.0 ± 
5.2, n = 7) compared to mice injected with saline (1.8 ± 1.4, n = 7), but this did not reach 
statistical significance (P = 0.2940) (Fig. 4b). hTNF-α expression was low, and similar in 
mice injected with BBG (0.1 ± 0.1, n = 7) or saline (0.1 ± 0.1, n = 7) (P = 0.7754) (Fig. 4c). 
Short-term BBG treatment reduces serum IFN-γ in allogeneic [18] and humanized [21] 
mouse models of GVHD. To determine if prolonged BBG treatment could alter the amount 
of these cytokines, serum hIFN-γ and hIL-17 concentrations in humanized NSG mice were 
assessed by ELISA. hIFN-γ was present in the serum of all mice (Fig. 4d). In contrast to 
previous data involving short-term BBG treatment [21], serum hIFN-γ concentrations were 
similar in mice injected with BBG (15.8 ± 10.7 ng/mL, n = 10) or saline (14.9 ± 8.4 ng/mL, n 
= 7) (P = 0.8462) (Fig. 4d). hIL-17 was not detected in the serum of any mice injected with 
BBG (n = 10) or saline (n = 7) using an ELISA with a reported sensitivity of 4 pg/mL 
(eBioscience). 
P2X7 expression is significantly increased in livers of mice with allogeneic GVHD [18]. 
Therefore, to determine the impact of P2X7 blockade on expression of hP2X7 and mP2X7, 
livers of humanized NSG mice were analyzed by qPCR. There was a four-fold increase in 
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relative hP2X7 expression in mice injected with BBG (8.7 ± 14.8, n = 7) compared to mice 
injected with saline (2.0 ± 1.5, n = 7), however this did not reach statistical significance (P = 
0.2547) (Fig. 4e). Relative mP2X7 expression was similar in mice injected with BBG (0.07 ± 
0.02, n = 7) or saline (0.07 ± 0.01, n = 7) (P = 0.9986) (Fig. 4f). 
 
4. Discussion 
The current study demonstrated that a long-term regime of P2X7 blockade using BBG (50 
mg/kg i.p. thrice weekly for up to 10 weeks) can reduce liver inflammation and apoptosis in a 
humanized mouse model of GVHD. Saline-injected control mice exhibited characteristic 
leukocyte infiltration and apoptosis in the liver, consistent with previous observations in 
humanized NSG mice [27, 28]. The long-term regime of BBG reduced leukocyte infiltrates, 
including human T cells, into the livers compared to control mice. This reduction was greater 
than our previous study using a short-term regime of BBG (50 mg/kg i.p. on days 0, 2, 4, 6, 
8) in humanized NSG mice [21]. Leukocyte infiltrates are also reduced in livers from 
allogeneic mice following a long-term regime of BBG (50 or 75 mg/kg i.p. twice weekly for 
four weeks) [20]. The long-term BBG regime in the current study also reduced apoptosis in 
livers, an effect that was greater than the previous short-term BBG regime in humanized NSG 
mice [21]. Similarly, the long-term BBG regime in allogeneic mice also reduced 
inflammatory damage [20]. The reduction in leukocyte infiltrates and apoptosis in livers is 
also similar to other GVHD therapies in humanized mice [28-30]. Notably, P2X7 blockade is 
an efficacious therapy in drug-induced inflammatory liver damage [31, 32]. Thus, the current 
and past [20] studies indicate that P2X7 is important for liver GVHD development and that 
P2X7 represents a potential therapeutic target in HSCT to prevent this form of GVHD.  
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The current study demonstrated that a long-term regime of BBG did not impact clinical 
disease in humanized mice. This result is similar to that of the short-term BBG regime in this 
model [21] but differs to that of a long-term BBG regime in the allogeneic mouse model of 
GVHD above [20]. In the latter study, BBG prevented weight loss, with a stronger effect 
observed with 75 mg/kg BBG compared to 50 mg/kg BBG, but clinical score and survival 
were not reported. Nevertheless, since the larger dose of 75 mg/kg significantly reduced 
histological GVHD and weight loss compared to the dose of 50 mg/kg in this allogeneic 
mouse model, investigation of this or larger doses in a humanized mouse model are 
warranted. Finally, it should be noted that administration of BBG into humanized NSG mice 
caused rapid weight gain, the reasons for which remain unknown. However, P2X7 blockade 
with BBG or P2RX7 gene deficiency also induces weight gain in C57BL/6 mice within one 
week [33]. This previous study hypothesized that a consensus motif similar to Janus kinase 2 
within the C-terminus of P2X7 may be a substrate of protein-tyrosine phosphatase 1B, which 
has known roles in obesity [34]. Thus, blockade of P2X7 may induce an initial weight gain in 
mice via modulation of this phosphatase. 
The long-term regime of BBG in the current study did not detect any differences in the 
expression of hIFN-γ, hIL-17, hTNF-α or mP2X7 in the livers of humanized mice. There was 
a two-fold, non-significant increase in hP2X7 in the liver, similar to the 1.7-fold increase in 
the short-term regime [21]. These results are somewhat unexpected given the reduced 
leukocyte infiltration and apoptosis in the livers of these mice. This suggests that other 
molecules may be controlling T cell migration and T cell-mediated damage in the livers of 
these mice. Alternatively, the similar expression of these molecules may simply reflect the 
comparison of livers at end-stage disease, but this does not explain observed differences in 
leukocyte infiltration and apoptosis. Analysis of liver samples earlier in disease progression 
may reveal further differences between BBG- and saline-treated mice.  
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Short-term [21] but not long-term BBG treatment (the current study) reduces serum hIFN-γ 
in humanized mice. The reason for this difference remains unknown, but suggests long-term 
P2X7 blockade negates any benefits observed with short-term P2X7 blockade in relation to 
serum hIFN-γ. This suggests that P2X7 blockade shortly after hPBMC engraftment reduces 
the development of hIFN-γ-producing T cells in humanized mice, similar to P2X7 deficiency 
reducing IFN-γ production early in disease development in allogeneic mice [35]. However, 
P2X7 blockade at later stages of engraftment and GVHD development may promote 
development of hIFN-γ-producing T cells in humanized NSG mice. Alternatively, 
comparison of serum hIFN-γ concentrations between the current and previous [21] studies 
indicates that the long-term regime with saline reduced serum hIFN-γ compared to the short-
term saline regime. This suggests long-term injections of saline may reduce some disease 
parameters in this humanized mouse model of GVHD. In support of this, injection of saline is 
used in other inflammatory disease models to rescue mice from weight loss [23, 36].  
Finally, the current study demonstrates that a long-term BBG regime does not affect 
engraftment of donor human cells in NSG mice. Although the clinical benefits of this regime 
were limited, this indicates long-term P2X7 blockade may permit reconstitution of the 
immune system, an essential aim of HSCT [37]. In the current study, the majority of 
engrafted leukocytes were T cells, consistent with previous studies [21, 27, 38]. Our previous 
study demonstrated that B cells are not present in the blood or spleens of humanized NSG 
mice, but the identity of the remaining human leukocytes remained unknown [21]. In the 
current study, NK cells constituted a portion of the remaining leukocyte population, 
consistent with similar frequencies of NK cells in humanized NSG mice observed by others 
[39, 40]. NK cells contribute to the graft-versus-leukemia effect but not GVHD in both mice 
[41] and humans [42], suggesting that NSG mice injected with hPBMCs could be potentially 
used to study the graft-versus-leukemia effect. Importantly, BBG did not affect NK cell 
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engraftment suggesting P2X7 blockade may not impact graft-versus-leukemia immunity, 
another key aim of HSCT. The current study also demonstrated, for the first time, that 
humanized NSG mice engraft a small proportion of NKT cells [43], although in the absence 
of additional markers these cells may represent activated T cells instead or in part [44]. NKT 
cells suppress GVHD in allogeneic HSCT in mice [45-47] and higher numbers of NKT cells 
in humans correlates to reduced GVHD [48, 49]. BBG did not alter the percentage of these 
cells indicating that P2X7 blockade does not affect engraftment of NKT cells. Thus, 
humanized NSG mice may help elucidate the role of human NK and NKT cells in GVHD. It 
should be noted that a limitation of the current study was that the flow cytometric analyzes 
did not include gating of singlets or dead cell exclusion using a viability dye. Thereby 
increasing the likelihood of small errors in determining the proportions of human leukocyte 
subsets especially rarer subsets such as NK and NKT cells. 
The current study demonstrated that long-term P2X7 blockade does not impact human 
leukocyte engraftment, weight loss, clinical score or mortality associated with GVHD. 
However, this regime can reduce leukocyte infiltration and apoptosis in the liver. Therefore, 
this study demonstrates that P2X7 activation plays a role in GVHD pathogenesis in the livers 
of humanized mice, supporting a role for this receptor in GVHD development in HSCT 
recipients. Moreover, given that long-term P2X7 blockade does not affect donor human 
leukocyte engraftment or appear to have any other adverse effects, P2X7 may represent a 
potential therapeutic target to reduce liver GVHD in HSCT recipients. Nevertheless, given 
that long-term P2X7 blockade appears to have similar benefits compared to short-term P2X7 
blockade in humanized NSG mice, the design of future mouse studies or clinical trials 
exploring the therapeutic benefits of P2X7 blockade in preventing GVHD need to consider 
the value of extended treatments with P2X7 antagonists. 
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Figures 
Figure 1. Long-term BBG treatment does not affect engraftment of human cells 
in a humanized mouse model of GVHD 
(a-k) NOD-SCID-IL2Rγnull (NSG) mice were injected intra-peritoneally (i.p.) with 10 x 106 
human (h) peripheral blood mononuclear cells (hPBMCs), and subsequently with saline (n = 
7) or saline containing Brilliant Blue G (BBG) (50 mg/kg) (n = 10) thrice weekly. The 
percentages of human leukocytes in (a-e) blood at 3 weeks post-hPBMC injection and (f-k) 
spleens at end-point were determined by flow cytometry. (a, f) hCD45+ leukocytes are 
expressed as a percentage of total mCD45+ and hCD45+ leukocytes. (b, g) hCD3+ hCD56-, (c, 
h) hCD3+ hCD56+, (d, i) hCD3- hCD56+ and (e, j) hCD3- hCD56- cells are expressed as a 
percentage of total hCD45+ leukocytes. (k) hCD4+ and hCD8+ T cell subsets are expressed as 
a percentage of total hCD3+ leukocytes. Data represents group means ± SD; symbols 
represent individual mice; *** P < 0.0001 compared to corresponding hCD8+ T cells.  
 
Figure 2.  Long-term BBG treatment does not affect disease development in a 
humanized mouse model of GVHD 
(a-c) Saline- and BBG-injected humanized NOD-SCID-IL2Rγnull (NSG) mice (Fig. 1) were 
monitored for (a) weight loss, (b) clinical score (using a scoring system, giving a total clinical 
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score out of 10), and (c) survival for up to 10 weeks. Data represents (a, b) group means ± SD 
or (c) percent survival (saline n = 7; BBG n = 10). 
 
Figure 3. Long-term BBG treatment reduces leukocyte infiltration and apoptosis 
in livers of a humanized mouse model of GVHD 
(a-c) Livers from saline- and BBG-injected humanized NOD-SCID-IL2Rγnull (NSG) mice 
(Fig. 1) at end-point were stained with (a) haematoxylin and eosin, (b) anti-human (h) CD3 
monoclonal antibody and haematoxylin or (c) terminal deoxynucleotidyl transferase 
deoxyuridine triphosphate nick-end and methyl green. (a-c) Images were captured by 
microscopy; representative images from one mouse per group shown; bar represents 100 μm. 
Image analysis was used to quantitate the mean number of cells per field of view from three 
different captured images per mouse. Data represents group means ± SD (saline n = 4-6; 
BBG n = 4-9); symbols represent individual mice; * P < 0.05 or ** P < 0.01 to saline. 
Figure 4.  Long-term BBG treatment does not affect serum or liver inflammatory 
markers in a humanized mouse model of GVHD 
(a-f) cDNA from livers of saline- and BBG-injected humanized NOD-SCID-IL2Rγnull (NSG) 
mice at end-point (Fig. 1) were used to assess the relative expression of human (h) (a) 
interferon (IFN)-γ, (b) interleukin (IL)-17, (c) tumor necrosis factor (TNF)-α, (e) hP2X7, and 
(f) murine (m) P2X7 by qPCR. (d) Concentrations of serum hIFN-γ from mice at end-point 
were analyzed by ELISA. (a-f) Data represents group means ± SD (saline n = 7; BBG n = 7-
9); symbols represent individual mice. 
Supplementary Figures 
Figure S1. Flow cytometric gating of leukocytes in blood and spleens from 
humanized mice  
(a-b) NOD-SCID-IL2Rγnull (NSG) mice were injected intra-peritoneally with 10 x 106 human 
(h) peripheral blood mononuclear cells, and subsequently with saline or saline containing 
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Brilliant Blue G (BBG) (50 mg/kg) thrice weekly. (a) Blood cells and (b) splenocytes from 
humanized NSG mice were labeled with isotype control or CD-specific monoclonal 
antibodies. (a, b) Leukocytes, initially gated by forward scatter (FSC-A) and side scatter 
(SSC-A), were analyzed to determine the percentages of human leukocytes (hCD45+ 
mCD45-), human T cells (hCD45+ mCD45- hCD3+ hCD56-), human NK cells (hCD45+ 
mCD45- hCD3- hCD56+), human NKT cells (hCD45+ mCD45- hCD3+ hCD56+), human non-
T/NK/NKT cells (hCD45+ mCD45- hCD3- hCD56-), and (spleen only) human CD4+ T cell 
(hCD3+ hCD4+ hCD8-), and human hCD8+ T cell (hCD3+ hCD4- hCD8+) subsets. 
Figure S2. Long-term BBG treatment does not affect intestinal or skin damage in 
a humanized mouse model of GVHD 
(a-b) NOD-SCID-IL2Rγnull (NSG) mice were injected intra-peritoneally (i.p.) with 10 x 106 
human (h) peripheral blood mononuclear cells (hPBMCs), and subsequently with saline or 
saline containing Brilliant Blue G (BBG) (50 mg/kg) thrice weekly. (a) Small intestines and 
(b) skin from hPBMC-injected mice injected with saline or BBG at end-point were stained 
with haematoxylin and eosin. Images were captured by microscopy; representative images 
from one mouse of seven saline- or 10 BBG-injected mice. (b) Image analysis was used to 
quantitate the mean epidermal thickness from three different skin images per mouse. Data 
represents group means ± SD (saline n = 6; BBG n = 7; P = 0.2174); symbols represent 
individual mice. 
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